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In mammals, complex I (NADH-ubiquinone oxidoreductase) of the mitochondrial respiratory chain
has 31 supernumerary subunits in addition to the 14 conserved from prokaryotes to humans. Mul-
tiplicity of structural protein components, as well as of biogenesis factors, makes complex I a sen-
sible pace-maker of mitochondrial respiration. The work reviewed here shows that the cAMP/PKA
pathway regulates the biogenesis, assembly and catalytic activity of complex I and mitochondrial
oxygen superoxide production. The structural, functional and regulatory complexity of complex I,
renders it particularly vulnerable to genetic and sporadic pathological factors. Complex I dysfunc-
tion has, indeed, been found, to be associated with several human diseases. Knowledge of the path-
ogenetic mechanisms of these diseases can help to develop new therapeutic strategies.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction
Complex I (NADH-ubiquinone oxidoreductase, E.C. 1.6.5.3) is
the ﬁrst enzyme of the mitochondrial respiratory chain, being the
entry port in the chain of the reducing equivalents of NADH, pro-
duced by mitochondrial dehydrogenases of respiratory substrates
[1–4]. The enzyme catalyzes the transfer of electrons from NADH
to ubiquinone in the inner mitochondrial membrane and conserves
the free energy, so made available, as a transmembrane electro-
chemical proton gradient (DlH+) according to reaction (1).al Societies. Published by Elsevier
Medical Sciences, Section of
oro, Bari, Italy. Fax: +39
.
ioenergetics (IBBE), ConsiglioNADHþ UQ þ 5Hþin $ NADþ þ UQH2 þ 4Hþout ð1Þ
The complex thus contributes by 40% to the generation of the
respiratory chain DlH+, which is utilized to make ATP from ADP
in the mitochondrial process of oxidative phosphorylation (OX-
PHOS) [4,5]. In human cells the ATP produced by OXPHOS covers,
under physiological conditions, more than 80% of the ATP that cells
need. This requirement is particularly stringent in organs like, for
example, the human brain, which even though it only represents
2% of the body weight, utilizes around 20% of all the oxygen we
consume [6].
Mammalian complex I, with a molecular mass of1  106 Da, is
the largest enzyme of the mitochondrial OXPHOS system. The com-
plex contains multiple redox centers: one FMN, nine iron–sulfur
(FeS)-centers and two protein bound semiquinones [1–4,7,8]. A
series of these provides the sequential, stepwise transfer of elec-
trons from NADH to the ubiquinone of the pool, coupled to protonB.V. Open access under CC BY-NC-ND license. 
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oxygen may, however, occur at different redox sites in the enzyme
[4,10–12].
In humans and mammals mitochondrial complex I has, in addi-
tion to the 14 subunits of the catalytic core, conserved from pro-
karyotes to humans, at least 31 supernumerary subunits [4,13].
Seven subunits of the complex are encoded by the mitochondrial
DNA, 38 by nuclear genes located in different chromosomes
[1,4,12,13]. What is the hidden code of these numerous supernu-
merary subunits? Some of them appear to be involved in the
assembly of the complex [4,14–17], its regulation [4,18] and ancil-
lary functions [4,19,20]. The GRIM-19 (B16.6) subunit, for example,
belongs to the group of genes associated with retinoid–interferon
induced mortality [19]. Moreover, a plethora of post-translational
modiﬁcations of complex I subunits have been detected. In partic-
ular, various subunits of the complex, NDUFS4 [21,22], NDUFB11
[23], NDUFA1 [23], NDUFA10 [24], NDUFA7 (B14.5a) [25] have
been found to be phosphorylated. Other post-translational modiﬁ-
cations have also been observed [26]. In addition, several proteins
have been identiﬁed which assure the proper assembly and stabil-
ity of the complex [27–29].
Complex I is a regulable pacemaker of the mitochondrial respi-
ratory function [15,30–32], is a major site of cellular oxygen super-
oxide production [10–12,33], is involved in apoptosis [34,35] and
age-related functional decline [36–38]. Various hormones, neuro-
transmitters and cell growth factors regulate, through the activa-
tion of cellular signal transduction networks, the expression and
functional activity of complex I [30,39–42].
Genetic dysfunctions of complex I represent, on the other hand,
the largest of primary mitochondrial diseases [43–46] and dys-
functions of the complex have been found in sporadic and familial
forms of Parkinson [47], cancer [48,49] and other disorders
[46,50,51].
Understanding the mechanisms of the biogenesis, energy trans-
duction, reactive oxygen species (ROS) production and regulation
of complex I is crucial to comprehend the pathophysiological role
of the complex in human diseases and to develop of therapeutical
strategies.
The present paper reviews features of the regulation by the
cAMP/PKA pathway of the biogenesis, functional capacity, ROS
interaction in complex I and the pathophysiological implication
of dysfunctions of the complex.
2. Complex I subunits are phosphorylated by the cAMP-
dependent protein kinase
Various mitochondrial proteins have been found in the phos-
phorylated form [52–54]. In the nineties our group discovered that
among the phosphorylated proteins of the inner mitochondrial
membrane, proteins of 18 and 6–10 kDa are structural subunits
of complex I. We showed that phosphorylation of these subunits
is catalyzed by the cAMP-dependent protein kinase (PKA)
[55,56]. Phosphorylation of complex I subunits can, in fact, be med-
iated by the PKA present in both the cytosol [57] and mitochondria
[58].
Edman sequencing of the electrophoretic protein band of
18 kDa of the puriﬁed bovine heart complex I showed the pres-
ence in this band of two subunits of the complex, namely the
GDHG and the AQDQ subunits (NDUFS4 gene) [21,22]. The position
of the latter corresponded to the band labeled by 32P in the
presence of PKA and [c-32P]ATP [21]. Chen et al. [23] conﬁrmed
PKA-dependent phosphorylation of protein(s) in bovine heart
mitochondria, and showed, in the 18 kDa 32P-labeled protein band
of complex I, an additional serine phosphorylated, previously unde-
tected [59], subunit (ESSS subunit) [23]. Two-dimensional IEF/SDS–PAGE electrophoresis of puriﬁed bovine heart complex I, 32P
labeling and immunoblotting with an antibody speciﬁc for the ser-
ine-173 phosphorylated C-terminus of the NDUFS4 protein, which
is conserved in animal species [22], showed that this site is phos-
phorylated by PKA. It was also shown that precursor and mature
human NDUFS4 protein produced by ‘‘in vitro’’ heterologous
expression, were both 32P-labeled when incubated with [c-32P]ATP
and PKA [22]. Thin layer chromatography amino-acid mapping of
radioactive proteins showed the presence of phosphothreonine
and phosphoserine both in the precursor and mature form of the
NDUFS4 protein [22]. S173A replacement in the conserved phos-
phorylation site resulted in disappearance of phosphoserine from
the mature form [22]. It should be mentioned that mass spectrom-
etry of the trypsin digest of the heterologous human NDUFS4 pro-
tein, phosphorylated by PKA, identiﬁed peptide ions of the protein
with 82% coverage of the sequence, but the in silico predicted car-
boxy terminal peptide ions of the last C-terminal 4–7 residues
were, however, not detected [22] see also [23]. It is worth noting
that this can be due to general problems in detection of this and
other phosphoproteins, like the low dynamic state of phosphoryla-
tion of the protein, loss of the C-terminus in the preparation/treat-
ment of the mass-spectrometer sample and the small size
(217.63m/z) of the terminal peptide ion generated by tryptic pro-
teolysis (see also [60]).
3. The cAMP/PKA pathway regulates complex I activity and ROS
balance in cell cultures
In mammalian cells there are subcellular pools of cAMP and
PKA [57,58,61–63]. In response to activation, by extracellular effec-
tors, the plasma membrane adenylyl cyclase (tmAC) produces and
releases cAMP in the cytosol, where its level is determined by the
opposite activities of the cyclase and phosphodiesterase(s) (Fig. 1)
[57,62].
Cytosolic cAMP cannot apparently move into the internal space
of subcellular organelles. There is, however, in the mitochondrial
matrix, and other organelles, a soluble bicarbonate-activable aden-
ylyl cyclase (sAC), which produces cAMP inside the organelles
(Fig. 1) [64–66].
All the members of the complex, involved in reversible cAMP-
dependent protein phosphorylation, are associated with the outer
[70] and the inner mitochondrial membrane [58,69,71]. The com-
plex consists of A-kinase anchor protein(s) (AKAPs) [58,67,68], cat-
alytic and regulatory subunits of PKA, phosphodiesterase(s) and
serine phosphatase(s) [58,67–71] (Fig. 1).
A strong depression of the NADH-ubiquinone oxidoreductase
activity of complex I, increase in the mitochondrial level of oxygen
superoxide and in the cellular level of hydrogen superoxide have
been observed in cells brought in the G0 phase by serum depriva-
tion [40,72], or impaired by genetic disorder [73,74] as well as in K-
ras oncogenic transformated cells [75]. It has to be recalled that
complex I, besides being the major mitochondrial producer of
ROS [4,10–12], is by itself particularly vulnerable to oxidative
stress [10,76]. The question remains open whether, under the con-
ditions described, it is a dysfunction in complex I that causes ROS
overproduction, or if it is the latter to cause inhibitory, oxidative
damage of the complex. The two processes can, in fact, set up a det-
rimental cycle.
In all the cases described, addition to the cells of a permeant
derivative of cAMP, or activation of tmAC by cholera toxin [40]
or the b-adrenoceptor agonist isoproterenol [42], reversed the
inhibition of complex I activity and the accumulation of ROS, with-
out having, however, any effect on ROS scavengers [40,42,72]. The
rescue effect exerted by cAMP production in response to activation
of tmAC, shows that, under these conditions at least, it is the
Fig. 1. Subcellular compartmentalization of the cAMP/PKA system. cAMP is produced by the plasma membrane adenylyl cyclase, in response to extracellular signals
[40,42,57] and by the bicarbonate-activated adenylyl cyclase localized in mitochondria and other subcellular structures [64–66]. Different subcellular pools of cAMP [63] can
thus be generated, with activation of PKA and other cAMP effectors. PKA, consisting of two cAMP-binding regulatory subunits (in green) and two catalytic subunits (in red),
dissociates upon binding of cAMP to the regulatory subunits (R-PKA). Speciﬁc AKAP proteins, associated with various subcellular membranes, bind R-PKA and in this way
tether the PKA tetramer to membranes together with speciﬁc protein phosphatases [58,62,67,68]. These complexes accomplish phosphorylation/dephosphorylation of
proteins bound or close to the complexes [67–69]. PKA has been found to be associated with both the outer [70] and the inner membrane/matrix fraction of mammalian
mitochondria [58] where it can phosphorylate various mitochondrial proteins. In the left inset a transmission electron microscopy picture of mitochondria isolated from rat
heart exposed to the AKAP121 antibody, conjugated with colloidal-gold secondary antibody is shown. Numerous gold particles of AKAP protein appear to be associated with
the mitochondrial cristae (from [58]).
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of complex I and to lower the ROS level, although also mitochon-
drial cAMP can provide an additional contribution.
Immunodetection with speciﬁc antibodies showed that in cell
cultures cAMP promoted, under the conditions in which it acti-
vated complex I and reversed ROS accumulation, phosphorylation
of serine [15,40,69] in the RVS site in the carboxy terminus of
the NDUFS4 protein [22]. Evidence that PKA-mediated phosphory-
lation of the NDUFS4 subunit is, indeed, responsible for the cAMP
activation of complex I, was clearly provided by the ﬁnding that
cAMP-dependent serine phosphorylation of complex I subunit(s)
and complex I activation were missing in patient’s ﬁbroblasts with
an NDUFS4 mutation, which caused disappearance of the protein
product of the gene from the cells [15,18]. It has also been found
that addition to cell cultures of phosphatase inhibitors also pro-
motes complex I activity [42].
The mechanism by which PKA dependent phosphorylation of
the NDUFS4 subunit, and possibly others, can result in activation
of complex I and lowering of ROS level is presented in the last part
of Section 4. In any case, the activation of complex I by cAMP/PKA
system shows that the functional capacity of the complex can re-
spond, in the cell, to a series of regulatory factors, which includeligands of plasma membrane receptors of the cAMP cascade, net-
works of cell signal transduction pathways, as well as metabolic
processes which contribute to cellular bicarbonate homeostasis
(see Fig. 1).
4. The cAMP/PKA system regulates the expression and the
assembly of complex I
In addition to the regulatory effects due to post-translational
protein phosphorylation, the cAMP/PKA system regulates also the
biogenesis of the mitochondrial OXPHOS system [41,77,78]. A cen-
tral role in this regulatory function is played by the cAMP/Ca2+ re-
sponse element (CRE) binding protein (CREB) [79]. CREB binds to
the DNA consensus sequence TGACGTCA in the promoters of target
nuclear genes [79]. The transcriptional activity of CREB is induced
by serine phosphorylation in its conserved kinase inducible do-
main by PKA, Ca2+/calmodulin protein kinases or other kinases
[80,81].
A role of CREB in mitochondrial biogenesis was highlighted by
the discovery that the CREB transcriptional complex activates the
expression of the master gene PGC-1a (the transcriptional coacti-
vator PPARc coactivator 1a) [93,94]. PGC-1a is also activated by
Fig. 2. Schematic representation of PKA and CREB mediated pathways, which control mitochondrial biogenesis. Activation of protein kinases by cAMP and/or Ca2+ results in
phosphorylation of CREB and TORCs proteins. Phosphorylated CREB and TORCs proteins bind to the CREB complex on gene promoters and exert their transcriptional
coactivator action [82]. CREB and TORC promote the transcription of PGC-1a and cytochrome c genes. PGC-1a is also activated by post-translational modiﬁcations, like
deacetylation by SIRT1 [83], phosphorylation by AMPK [84] and inhibited by phosphorylation by the insulin activated AKT [85]. The expression of PGC-1a can be regulated at
transcriptional level by methylation of the promoter, as found in type II diabetes in which hypermethylation of the promoter inhibits transcription [86]. The diet also
inﬂuences the expression of PGC-1a. Caloric restriction, and thus the AMP/ATP and NAD+/NADH ratios, regulate the activities of AMPK and SIRT1 respectively [87,88]. A diet
rich in polyunsaturated fatty acids apparently promotes, one rich in saturated fatty acids down-regulates PGC-1a expression [89]. Several compounds present in the diet like
hydroxytyrosol of olive oil [90], and resveratrol of red wine [91], regulate the expression of PGC-1a. PGC-1a, in combination with other factors, activates the expression of the
nuclear respiratory transcription factors, NRF1 and NRF2. NRF1 and NRF2 activate the expression of the mitochondrial transcription and replication factors (TFAM, TFB1M,
TFB2M and MRP RNA) and nuclear genes coding for structural proteins and assembly factors of OXPHOS complexes, mitochondrial import, ion channel and shuttle proteins.
The CREB protein, after mitochondrial import, promotes the expression of mtDNA [78]. Recently PGC-1a and SIRT1 have been found also in mitochondria, where they
physically interact with mTFA [92].
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dependent deacetylase sirtuin-1 (SIRT1) [83], whose expression is
promoted by fasting [88]. Compounds present in the diet like
hydroxytyrosol of olive oil [90], and resveratrol of red wine [91],
regulate the expression of PGC-1a, through the activation of AMP
kinase, and/or SIRT1 (Fig. 2).
Induced expression of PGC-1a activates a transcriptional regu-
latory cascade, which ampliﬁes the impact of CREB-mediated sig-
nal transduction on mitochondrial biogenesis [94]. PGC-1a
promotes the expression and activity of the nuclear respiratory
transcription factors 1 and 2 (NRF1 and NRF2) [95]. NRF1 and
NRF2 control the expression of nuclear genes coding for structural
proteins of mitochondrial respiratory chain and the FoF1-ATP syn-
thase, enzymes of heme biosynthesis and proteins involved in
mitochondrial import of nuclear encoded subunits of OXPHOS
complexes and complex assembly (Fig. 2) [96].
NRF1 and NRF2 also promote replication and transcription of
the mitochondrial genome (see Fig. 2) [96]. The transcriptional
activity of both the heavy and light mtDNA strands is controlled
by the mitochondrial transcriptional factor A (TFAM). This interacts
with the mitochondrial RNA polymerase [97] together with two
additional transcription factors (mitochondrial transcription factor
TFB1M and TFB2M) and a fraction of PGC-1a found in mitochon-
dria [92]. In this way, a transcriptional cascade (Fig. 2) confers to
mammalian cells the capacity to upregulate in a concerted process
the expression of nuclear and mitochondrial genes encoding sub-
units of OXPHOS complexes.
It has been discovered that, in addition to the nucleus, CREB is
also localized in the inner mitochondrial compartment [98]. In
neuronal cell cultures CREB protein was found to bind to the
mtDNA D-loop [99]. In these cells, the overexpression of mito-
tagged CREB increased the transcript levels of the ND2, ND4, and
ND5 mitochondrial genes of complex I. We have found [78] that
‘‘in vitro’’ expressed [35S] methionine-labeled CREB is imported in
isolated mitochondria by the membrane potential-dependent
mechanism [100]. Both mitochondrial surface binding and import
into the inner mitochondrial compartment of radioactive CREB
was inhibited by an antibody against Tom20 (outer membranetranslocator subunit 20) [78]. CREB protein, once imported in mito-
chondria, produced a strong stimulation of the synthesis of sub-
units of OXPHOS complexes encoded by mitochondrial genes, an
effect that required CREB phosphorylation by PKA [78]. The stimu-
latory effect was particularly potent in the case of ND1, ND6, and
cox III/ATP6 proteins, whose synthesis was two- to three-fold en-
hanced by the combination of CREB and cAMP [78].
The assembly of a mature, functional complex in the inner mito-
chondrial membrane is achieved in a multi-step process which, in
addition to the quantitatively coordinated expression of the 38
nuclear-encoded and the seven mitochondrial-encoded subunits,
involves: (i) chaperon-assisted folding changes of the newly
synthesized proteins; (ii) mitochondrial import of the nuclear-en-
coded precursor proteins through the outer membrane (TOM)
and inner membrane (TIM) translocator systems; (iii) proteolytic
maturation of the precursor proteins; (iv) stepwise incorporation
in the complex, in which one copy of each subunit has to be
incorporated in the proper near-neighbor functional position
[27–29,46]. In addition, the synthesis and assembly of the protein
subunits has to be coordinated with the production and the correct
binding at the catalytic centers of FMN and non-heme iron–sulfur
centers [101].
It has been found that, in addition to de novo synthesis of an en-
tire complex from all the individual subunits, an exchange of indi-
vidual subunits, in particular those more superﬁcially located in
the complex, with newly synthesized subunits can also take place
[102].
Work in our laboratory showed that the Dw dependent import
in isolated mitochondria of [35S]-methionine labeled NDUFS4 pre-
cursor protein, produced ‘‘in vitro’’ by expression of the full-length
NDUFS4 cDNA, is promoted when it is phosphorylated by added
PKA and inhibited by phosphatase (Fig. 3) [103].
The import/maturation in mitochondria of the NDUFS4 protein,
completed in the same time-span in which cAMP stimulated com-
plex I activity in cell cultures, was completely suppressed by site-
speciﬁc substitution of serine 173 with alanine in the C-terminal
RVS phosphorylation site. These observations, showing that the
functional capacity of complex I depends on phosphorylation and
Fig. 3. Scheme describing the impact of the cAMP/PKA system on the mitochondrial import of the NDUFS4 subunit and its assembly in complex I. Elevation of the cytosolic
level of cAMP by stimulation of plasma membrane adenylyl cyclase results in PKA-dependent phosphorylation of the NDUFS4 C-terminus. This promotes the binding of the
NDUFS4 precursor to the cytosolic heat shock protein 70 (Hsp70). Phosphorylated NDUFS4 precursor is imported into mitochondria where it undergoes to cleavage of the
presequence [103]. Newly imported NDUFS4 protein (in green) is assembled in complex I during de novo synthesis of the complex or in exchange with the pre-existing
(damaged, in red) subunit in the mature complex.
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posed mechanism of exchange of subunits in the assembled com-
plex with newly imported ones to maintain complex I
homeostasis (Fig. 3) [102]. This process can, in fact, play a proof-
checking role for subunits, superﬁcially exposed to the matrix
space where they can be oxidatively-damaged by ROS, with
depression of the catalytic activity of the complex. Substitution
of the oxidatively damaged subunits with newly synthesized ones
can play a role in the functional rescue of complex I. Oxidation of
complex I subunits, accompanied by reduced functional capacity
of the complex, have been observed in aging [37,38]. Results from
the author’s laboratory has shown that oxidation of complex I sub-
units, by the addition to ﬁbroblast cell cultures of ROS generating
tert-butyl hydroperoxide, depressed the functional capacity of
complex I. Activation of the cAMP/PKA system promoted the im-
port of newly synthesized NDUFS4 subunit into mitochondria
and restored its dynamic assembly (unpublished observations).
5. Genetic dysfunctions of complex I are associated with
different human diseases
Isolated complex I deﬁciency is the most frequent case of pri-
mary mitochondrial defects [43–46]. Complex I pathological muta-
tions have been initially found in mitochondrial-DNA encoded
subunits [104]. The ﬁrst fatal mutation in a nuclear gene of com-
plex I, detected in a newborn [105], was a base duplication in exon
5 of the NDUFS4 gene encoding the 18 kDa AQDQ subunit of the
complex, previously found to be phosphorylated by PKA [21]. Later,other mutations in the NDUFS4 gene were detected in different
encephalopathic patients [46]. In all these cases the NDUFS4 muta-
tions resulted in: (i) disappearance of the protein from the patient’s
cells; (ii) suppression of the last step in complex I assembly; (iii)
disappearance of cAMP dependent serine phosphorylation of com-
plex I subunits and of the stimulatory effect of cAMP on mitochon-
drial respiration; (iv) stabilization of alternative splice products of
the gene [46]. In the NDUFS4 mutations, which resulted in com-
plete suppression of the NADH-ubiquinone oxidoreductase activity
of complex I, no ROS accumulation was observed [73].
A pathological C1564Amutation was also detected in the nucle-
ar NDUFS1 gene coding for the 75 kDa iron–sulfur protein subunit
of complex I [73]. This is the largest conserved subunit of the com-
plex and contains the N1b, N4, N5 Fe–S clusters of the electron
transfer pathway in the enzyme [7–9].
In the ﬁbroblasts of the patient harboring the C1564A mutation
(Q522K substitution in the protein), the mitochondrial content of
the normally assembled complex decreased as compared to normal
cells and an additional lower molecular mass of the complex
appeared [73]. The mutation resulted also in a marked, but not
complete, suppression of the NADH-ubiquinone oxidoreductase
activity. In the patient’s ﬁbroblasts large accumulation of H2O2
and intramitochondrial O2 was detected. The Q522K mutation in
the NDUFS1 subunit alters, apparently, the redox function of the
Fe–S center(s) bound to this protein, with inhibition of the normal
catalytic activity of the complex and increased production of
oxygen superoxide. The enhanced production of ROS can in turn
cause further oxidative damage in a ‘‘vicious cycle’’ leading to
Fig. 4. (Panel A) Structure of the NDUFS4 human gene of complex I with location of pathological mutations found in neurological patients with complex I deﬁciency. In the
Table ﬁve exonic mutations, one intronic mutation shown in the structure of the gene and a sixth mutation with deletion of a region including exons 3 and 5, with the
associated diseases are listed. For details see text and the references in the table. (Panel B), alternative splicing products of the NDUFS4 gene detected in human ﬁbroblasts.
The scheme shows the mechanism of production of the alternative splicing products normally produced by the NDUFS4 gene but up-regulated in the exonic 44G–A mutation
as well as in the intronic IVS1nt-1, G–A mutation. For details see text and refs. [105,108–112].
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The depression of the activity of complex I was counteracted by
the addition to the ﬁbroblast culture of dibutyryl-cAMP, which also
prevented the accumulation of oxygen free radicals [73]. Selected
antioxidants and b-agonists could offer a rational therapeutical
strategy in patients carrying mutations in NDUFS1 or in other com-
plex I genes, which result in a dysfunction centered on excess of
ROS production and oxidative stress.
A more recent example of how a dysfunction in the cAMP/PKA
system can result in a detrimental impairment of the catalytic
activity of complex I and overproduction of ROS was provided by
a study of the mitochondrial bioenergetic function in human skin
ﬁbroblasts of Down Syndromes patients [74]. Down Syndrome is
a multifactorial disorder caused by trisomy of human chromosome
21, resulting in mental retardation, premature aging and neurode-
generation. A strong decrease in the cellular level of cAMP and
depression of PKA activity were found in the patient’s ﬁbroblasts
[74]. The serine phosphorylation of the NDUFS4 subunit and the
catalytic activity of complex I were markedly reduced and the level
of mitochondrial oxygen superoxide and cellular H2O2 increased in
the patient’s ﬁbroblasts. All these changes were reversed by the
addition to the ﬁbroblasts of dibutyryl-cAMP. These observations,
besides contributing to understand the pathogenetic mechanism
of the Down Syndrome, may help to develop therapeutical ap-
proaches based on the use of b-adrenoceptor agonists which, as
previously reported, rescue complex I deﬁciency and decrease
ROS levels in human cell cultures.It can also be mentioned that work in progress along other lines
in the author’s laboratory, in collaboration with the Department of
Biotechnology and Biosciences, University of Milano-Bicocca,
showed that K-ras oncogenic expression in ‘‘in vitro’’ transformed
cells and in human tumors was associated with a dysregulation
of the cAMP/PKA pathway. This appeared to result in fragmenta-
tion of mitochondria and depression of complex I activity. These
defects also were all rescued by promoting formation of cAMP with
forskolin (unpublished observations).
6. Pathological mutations of the NDUFS4 subunit of complex I
stabilize alternative splice transcripts of the gene
A study of the NDUFS4 gene transcription in patients with path-
ological mutations of the gene revealed new features of surveil-
lance mechanisms regulating the levels of alternative transcripts
[106,107]. The ﬁve exons of the gene result in a canonical mRNA
coding for the 175 residues precursor protein of the 18 kDa (AQDQ)
subunit of complex I [22] (Fig. 4).
In a patient with a 44G? A, nonsense mutation, in the ﬁrst
exon caused, as expected, disappearance of the mature protein.
This mutation which introduced a premature termination codon
(PTC) in the proximity of the canonical AUG start codon, rather
than eliciting nonsense mediated decay (NMD) degradation of
the canonical mRNA, upregulated three PTC containing alternative
transcripts (splice variants 1, 2 and 3) (Fig. 4) [106,107]. The splice
variants 1 and 2 (SV1 and SV2) result from insertion between
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sites (Fig. 4). The splice variant 3 (SV3) derives from exon 2 skip-
ping. These three alternative transcripts are also produced in nor-
mal cells, but their level is kept low by different RNA surveillance
mechanisms. SV1 and SV2 were found to be degraded in the cyto-
sol by NMD, the level of SV3 was down-regulated directly in the
nucleus by a process different from NMD, which affected the pro-
duction of the transcript rather than its stability [107]. In the pa-
tient ﬁbroblasts the 44G? A nonsense mutation inactivated
NMD degradation of SV1 and SV2 and nuclear down regulation
of SV3 (Fig. 4). In a neurological patient with a homozygous splice
acceptor site mutation in intron 1 (IVS1nt-1, G? A) of the NDUFS4
gene (Fig. 4) only a mRNA transcript, in which exon 2 was skipped,
was detected [111]. Ampliﬁcation of this transcript and sequencing
showed that it corresponded to the PTC containing SV3 isoform de-
tected in the patient with 44 G? A nonsense exonic mutation in
the NDUFS4 gene (Fig. 4) [107]. The accumulation of the aberrant
alternative transcripts, caused by exonic or intronic mutation in
the NDUFS4 gene, able to escape the mRNA surveillance mecha-
nisms, can represent another deleterious event contributing to
the pathogenetic mechanism of the NDUFS4 mutations in neuro-
logical patients. In vitro translation experiment showed, in fact,
that the aberrant alternative transcripts were able to produce po-
tential toxic proteins [107].
7. Selective degradation of the NDUFS3 subunit of complex I. An
involvement of granzyme Amediated NDUFS3 cleavage in type I
diabetes?
Type I diabetes is an autoimmune disease in which, killer lym-
phocytes (natural killer and cytotoxic T lymphocytes) destroy the
insulin producing b-cells of the pancreas [113]. The destruction
of b-cells by lymphocytes involves: formation of immune synapse
through lymphocyte-binding to class I hystocompatibility complex
proteins on the surface of b-cells [113] and perforin mediated
injection into b-cells of members of granzyme serine proteases,
where they initiate a cascade of events leading to cell death
[113]. A mechanism of cell death induced by granzyme B has been
proposed that involves caspase and Bid-dependent apoptosis
[113].
Recent work has provided evidence showing that killer lympho-
cytes can induce a caspase independent cell death by delivery of
granzyme A into mitochondria of the target cells [114]. Granzyme
A once entered into the inner mitochondrial compartment digests,
selectively, the NDUFS3 subunit of complex I [114]. Degradation of
this subunit results in inhibition of the normal catalytic activity of
the complex and promotion of its capacity to produce ROS. Eleva-
tion of the cellular ROS level is proposed to trigger a series of
downstream events, which include translocation of the endoplas-
mic reticulum-associated SET complex into the nucleus, where
its cleavage by granzyme A induces the release of proteins, respon-
sible for DNA fragmentation and ultimately cell death [114].
Mitochondrial proteomic analysis, carried out in our laboratory,
has revealed a selective decrease of the content of the NDUFS3 sub-
unit of complex I in brain mitochondria of rats in which insulin-
deﬁcient type I diabetes was induced by streptozotocin treatment.
The decreased content of the NDUFS3 subunit, which was essen-
tially due to post-transcriptional events, resulted in a severe
impairment of the enzymatic activity of complex I (unpublished
observations).
How insulin deﬁciency, hyperglycemia and/or other secondary
alterations do result in the selective degradation of the NDUFS3
subunit of complex I in the brain of diabetic rats remains to be clar-
iﬁed. It is possible that the streptozoticin-induced diabetes results
in activation of granzyme A or of different endogenous protease(s)
in neuronal mitochondria (see also Ref. [114]). Is it possible thatselective NDUFS3 degradation by granzyme A is critically involved
in a mechanism of destruction of pancreatic b-cells in human dia-
betes? (see also Ref. [115]).
8. Conclusions
The work presented provides an appraisal of the regulation by
the cAMP/PKA pathway of the expression, assembly and catalytic
activity of complex I of the mitochondrial respiratory chain in hu-
mans and mammals. The control of complex I functional capacity
and of ROS production/level by the cAMP/PKA pathway has far-
reaching implications in human pathophysiology. Complex I is a
pace-maker of the overall activity of mitochondrial oxidative phos-
phorylation. In organs like brain, heart, kidney, skeletal muscle,
and others, which undergo changes from rest to various degrees
of activity, the ATP production by OXPHOS has to respond to the
continually changing energy demand. Complex I with its abun-
dance of structural and ancillary proteins offers the prerequisites
to respond to a variety of regulatory stimuli. Regulation of complex
I by the cAMP/PKA pathway, which is at the cross-road of signal
transduction networks, ampliﬁes the signals to which mitochon-
drial respiratory metabolism can respond. The same complexity
of the regulatory network of complex I makes it particularly vul-
nerable to gene mutations, as well as to sporadic, endogenous
and exogenous factors. The deleterious consequence of this, is, in
fact, underlined by the discoveries of the different human diseases
in which complex I dysfunction was, so far, found to play a deter-
minant role. The possibility emerges, from what reported, of new
therapeutical strategies for diseases in which combined dysregula-
tion of the cAMP/PKA pathway and of complex I are involved.
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